Celgene and BMS-backed cancer therapy developer Repare Therapeutics has filed to go public after raising more than $165m in equity financing.

Ping An Global Voyager Fund has led a $35.4m series C round for the dental aligner producer that will drive continued expansion efforts across Europe.

Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance and Ascension Ventures all took part in the cancer data provider's latest round.

Illumina, General Atlantic and Viking Global have supplied $70m for Ginkgo Bioworks, an MIT spinout that has now raised more than $789m altogether.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Q32 Bio has launched with $46m from investors including University of Colorado to target autoimmune and inflammatory diseases.

Illumina, General Atlantic and Viking Global Investors supplied $70m for Ginkgo Bioworks, a cell programming technology provider that has now raised more than $789m altogether.

Existing backer Ligand took part in a series C round that will fund late-stage clinical trials for Palvella Therapeutics' rare genetic disease drug candidates.

Q32 Bio has launched with $46m from investors including Sanofi Ventures and Children’s Hospital Colorado to target autoimmune and inflammatory diseases.

Atom Bioscience will use the capital from the series B round, which was co-led by Livzon Pharmaceutical, to advance its gout treatment into phase 2 trials.